Insider Transactions in Q4 2025 at Exact Sciences Corp (EXAS)
Insider Transaction List (Q4 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 24
2025
|
Brian Baranick EVP, GM, Precision Oncology |
SELL
Payment of exercise price or tax liability
|
Direct |
14,938
-12.57%
|
$1,508,738
$101.59 P/Share
|
|
Dec 24
2025
|
Brian Baranick EVP, GM, Precision Oncology |
BUY
Grant, award, or other acquisition
|
Direct |
29,416
+19.85%
|
-
|
|
Dec 23
2025
|
Aaron Bloomer EVP, Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
27,954
-25.45%
|
$2,823,354
$101.82 P/Share
|
|
Dec 23
2025
|
Aaron Bloomer EVP, Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
63,099
+35.78%
|
-
|
|
Dec 23
2025
|
James Herriott SVP, General Counsel & Sec |
SELL
Payment of exercise price or tax liability
|
Direct |
49,870
-13.18%
|
$5,036,870
$101.82 P/Share
|
|
Dec 23
2025
|
James Herriott SVP, General Counsel & Sec |
BUY
Grant, award, or other acquisition
|
Direct |
72,320
+22.4%
|
-
|
|
Dec 23
2025
|
James Herriott SVP, General Counsel & Sec |
BUY
Exercise of conversion of derivative security
|
Direct |
33,780
+20.53%
|
-
|
|
Dec 23
2025
|
Kevin T Conroy President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
335,549
-9.14%
|
$33,890,449
$101.82 P/Share
|
|
Dec 23
2025
|
Kevin T Conroy President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
713,931
+32.39%
|
-
|
|
Dec 23
2025
|
Sarah Condella EVP, Human Resources |
SELL
Payment of exercise price or tax liability
|
Direct |
41,938
-5.88%
|
$4,235,738
$101.82 P/Share
|
|
Dec 23
2025
|
Sarah Condella EVP, Human Resources |
BUY
Grant, award, or other acquisition
|
Direct |
42,018
+12.56%
|
-
|
|
Dec 23
2025
|
Sarah Condella EVP, Human Resources |
BUY
Exercise of conversion of derivative security
|
Direct |
47,208
+9.86%
|
-
|
|
Dec 23
2025
|
Brian Baranick EVP, GM, Precision Oncology |
SELL
Payment of exercise price or tax liability
|
Direct |
69,159
-15.09%
|
$6,985,059
$101.82 P/Share
|
|
Dec 23
2025
|
Brian Baranick EVP, GM, Precision Oncology |
BUY
Grant, award, or other acquisition
|
Direct |
63,107
+23.37%
|
-
|
|
Dec 23
2025
|
Brian Baranick EVP, GM, Precision Oncology |
BUY
Exercise of conversion of derivative security
|
Direct |
73,080
+22.07%
|
-
|
|
Dec 23
2025
|
Jacob A Orville EVP, GM, Screening |
SELL
Payment of exercise price or tax liability
|
Direct |
68,437
-12.33%
|
$6,912,137
$101.82 P/Share
|
|
Dec 23
2025
|
Jacob A Orville EVP, GM, Screening |
BUY
Grant, award, or other acquisition
|
Direct |
72,523
+17.85%
|
-
|
|
Dec 23
2025
|
Jacob A Orville EVP, GM, Screening |
BUY
Exercise of conversion of derivative security
|
Direct |
73,080
+21.52%
|
-
|
|
Nov 19
2025
|
James Herriott SVP, General Counsel & Sec |
SELL
Open market or private sale
|
Direct |
1,000
-7.95%
|
$70,000
$70.0 P/Share
|
|
Nov 19
2025
|
Jacob A Orville EVP, GM, Screening |
SELL
Open market or private sale
|
Direct |
5,000
-17.71%
|
$375,000
$75.0 P/Share
|
|
Nov 04
2025
|
Brian Baranick EVP, GM, Precision Oncology |
SELL
Open market or private sale
|
Direct |
2,858
-11.33%
|
$200,060
$70.08 P/Share
|
|
Nov 04
2025
|
James Herriott SVP, General Counsel & Sec |
SELL
Open market or private sale
|
Direct |
1,500
-10.65%
|
$105,000
$70.08 P/Share
|
|
Oct 24
2025
|
Katherine S Zanotti |
SELL
Open market or private sale
|
Direct |
12,000
-16.49%
|
$780,000
$65.0 P/Share
|
|
Oct 09
2025
|
James Edward Doyle |
SELL
Open market or private sale
|
Direct |
2,000
-3.34%
|
$120,000
$60.0 P/Share
|
|
Oct 09
2025
|
James Herriott SVP, General Counsel & Sec |
SELL
Open market or private sale
|
Direct |
1,500
-9.62%
|
$90,000
$60.0 P/Share
|